Clinical Oncology Next Generation Sequencing Market (By Workflow: NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis; By Technology; By Application; By End Use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2025-2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Clinical Oncology Next Generation Sequencing Market 

5.1. COVID-19 Landscape: Clinical Oncology Next Generation Sequencing Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Clinical Oncology Next Generation Sequencing Market, By Technology

8.1. Clinical Oncology Next Generation Sequencing Market, by Technology

8.1.1. Whole Genome Sequencing

8.1.1.1. Market Revenue and Forecast

8.1.2. Whole Exome Sequencing

8.1.2.1. Market Revenue and Forecast

8.1.3. Targeted Sequencing & Resequencing

8.1.3.1. Market Revenue and Forecast

Chapter 9. Global Clinical Oncology Next Generation Sequencing Market, By Workflow

9.1. Clinical Oncology Next Generation Sequencing Market, by Workflow

9.1.1. NGS Pre-Sequencing

9.1.1.1. Market Revenue and Forecast

9.1.2. NGS Sequencing

9.1.2.1. Market Revenue and Forecast

9.1.3. NGS Data Analysis

9.1.3.1. Market Revenue and Forecast

Chapter 10. Global Clinical Oncology Next Generation Sequencing Market, By Application 

10.1. Clinical Oncology Next Generation Sequencing Market, by Application

10.1.1. Screening

10.1.1.1. Market Revenue and Forecast

10.1.2. Companion Diagnostics

10.1.2.1. Market Revenue and Forecast

10.1.3. Others

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Clinical Oncology Next Generation Sequencing Market, By End Use 

11.1. Clinical Oncology Next Generation Sequencing Market, by End Use

11.1.1. Hospitals

11.1.1.1. Market Revenue and Forecast

11.1.2. Clinics

11.1.2.1. Market Revenue and Forecast

11.1.3. Laboratories

11.1.3.1. Market Revenue and Forecast

Chapter 12. Global Clinical Oncology Next Generation Sequencing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Technology

12.1.2. Market Revenue and Forecast, by Workflow

12.1.3. Market Revenue and Forecast, by Application

12.1.4. Market Revenue and Forecast, by End Use

12.1.5. U.S.

12.1.5.1. Market Revenue and Forecast, by Technology

12.1.5.2. Market Revenue and Forecast, by Workflow

12.1.5.3. Market Revenue and Forecast, by Application

12.1.5.4. Market Revenue and Forecast, by End Use

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Forecast, by Technology

12.1.6.2. Market Revenue and Forecast, by Workflow

12.1.6.3. Market Revenue and Forecast, by Application

12.1.6.4. Market Revenue and Forecast, by End Use

12.2. Europe

12.2.1. Market Revenue and Forecast, by Technology

12.2.2. Market Revenue and Forecast, by Workflow

12.2.3. Market Revenue and Forecast, by Application

12.2.4. Market Revenue and Forecast, by End Use

12.2.5. UK

12.2.5.1. Market Revenue and Forecast, by Technology

12.2.5.2. Market Revenue and Forecast, by Workflow

12.2.5.3. Market Revenue and Forecast, by Application

12.2.5.4. Market Revenue and Forecast, by End Use

12.2.6. Germany

12.2.6.1. Market Revenue and Forecast, by Technology

12.2.6.2. Market Revenue and Forecast, by Workflow

12.2.6.3. Market Revenue and Forecast, by Application

12.2.6.4. Market Revenue and Forecast, by End Use

12.2.7. France

12.2.7.1. Market Revenue and Forecast, by Technology

12.2.7.2. Market Revenue and Forecast, by Workflow

12.2.7.3. Market Revenue and Forecast, by Application

12.2.7.4. Market Revenue and Forecast, by End Use

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Forecast, by Technology

12.2.8.2. Market Revenue and Forecast, by Workflow

12.2.8.3. Market Revenue and Forecast, by Application

12.2.8.4. Market Revenue and Forecast, by End Use

12.3. APAC

12.3.1. Market Revenue and Forecast, by Technology

12.3.2. Market Revenue and Forecast, by Workflow

12.3.3. Market Revenue and Forecast, by Application

12.3.4. Market Revenue and Forecast, by End Use

12.3.5. India

12.3.5.1. Market Revenue and Forecast, by Technology

12.3.5.2. Market Revenue and Forecast, by Workflow

12.3.5.3. Market Revenue and Forecast, by Application

12.3.5.4. Market Revenue and Forecast, by End Use

12.3.6. China

12.3.6.1. Market Revenue and Forecast, by Technology

12.3.6.2. Market Revenue and Forecast, by Workflow

12.3.6.3. Market Revenue and Forecast, by Application

12.3.6.4. Market Revenue and Forecast, by End Use

12.3.7. Japan

12.3.7.1. Market Revenue and Forecast, by Technology

12.3.7.2. Market Revenue and Forecast, by Workflow

12.3.7.3. Market Revenue and Forecast, by Application

12.3.7.4. Market Revenue and Forecast, by End Use

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Forecast, by Technology

12.3.8.2. Market Revenue and Forecast, by Workflow

12.3.8.3. Market Revenue and Forecast, by Application

12.3.8.4. Market Revenue and Forecast, by End Use

12.4. MEA

12.4.1. Market Revenue and Forecast, by Technology

12.4.2. Market Revenue and Forecast, by Workflow

12.4.3. Market Revenue and Forecast, by Application

12.4.4. Market Revenue and Forecast, by End Use

12.4.5. GCC

12.4.5.1. Market Revenue and Forecast, by Technology

12.4.5.2. Market Revenue and Forecast, by Workflow

12.4.5.3. Market Revenue and Forecast, by Application

12.4.5.4. Market Revenue and Forecast, by End Use

12.4.6. North Africa

12.4.6.1. Market Revenue and Forecast, by Technology

12.4.6.2. Market Revenue and Forecast, by Workflow

12.4.6.3. Market Revenue and Forecast, by Application

12.4.6.4. Market Revenue and Forecast, by End Use

12.4.7. South Africa

12.4.7.1. Market Revenue and Forecast, by Technology

12.4.7.2. Market Revenue and Forecast, by Workflow

12.4.7.3. Market Revenue and Forecast, by Application

12.4.7.4. Market Revenue and Forecast, by End Use

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Forecast, by Technology

12.4.8.2. Market Revenue and Forecast, by Workflow

12.4.8.3. Market Revenue and Forecast, by Application

12.4.8.4. Market Revenue and Forecast, by End Use

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Technology

12.5.2. Market Revenue and Forecast, by Workflow

12.5.3. Market Revenue and Forecast, by Application

12.5.4. Market Revenue and Forecast, by End Use

12.5.5. Brazil

12.5.5.1. Market Revenue and Forecast, by Technology

12.5.5.2. Market Revenue and Forecast, by Workflow

12.5.5.3. Market Revenue and Forecast, by Application

12.5.5.4. Market Revenue and Forecast, by End Use

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Forecast, by Technology

12.5.6.2. Market Revenue and Forecast, by Workflow

12.5.6.3. Market Revenue and Forecast, by Application

12.5.6.4. Market Revenue and Forecast, by End Use

Chapter 13. Company Profiles

13.1. Illumina, Inc.

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Thermo Fisher Scientific

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. F. Hoffmann-La Roche Ltd.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Agilent Technologies

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. Myriad Genetics

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Perkin Elmer

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. Pacific Bioscience

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Oxford Nanopore Technologies Ltd.

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. Eurofins Scientific S.E.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Qiagen N.V.

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms